Skip to content

BREAKING NEWS: FDA Approves First Treatment for Friedreich’s Ataxia. LEARN MORE!

National Ataxia Foundation

2023 AAC

Clinical Trials

Snapshot: What is Riluzole?

Riluzole, often sold under the trade name Rilutek, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease that mainly affects neurons controlling muscle movements. The drug was approved by the FDA (1995), Health Canada (1997), and the European Commission (1996). It Read More…

Snapshot: What is Omaveloxolone?

A new therapeutic compound shows promise to treat Friedrich’s ataxia. What is Friedrich’s ataxia (FA)? Friedrich’s ataxia is a genetic neurodegenerative disease that affects many organs, most notably nerves, muscles, and heart. FA is a recessive ataxia. Symptoms typically present in childhood and result in significant physical disability. Cognition (thinking, Read More…

Snapshot: What are Clinical Trials?

How does a medical drug get to patients? Research is being done every day to discover new or better ways to treat diseases and various medical conditions. In order to determine if these treatments will help patients, studies known as “clinical trials” need to be done before these methods of Read More…

Translate »
National Ataxia Foundation

Join NAF

Become a member for FREE!
It only takes a few moments.

Sign up today to receive:

  • News and research opportunities about your specific type of Ataxia as they become available
  • Early access to free webinars
  • eNewsletter and Generations publications